Good Doctor Pharmaceutical Group Co., Ltd., founded in 1998 and based in Mianyang, Sichuan Province, has grown into a large enterprise that integrates science, industry, and commerce with a focus on biopharmaceuticals as part of its comprehensive development in the "big health" industry. The group's businesses span seven sectors: pharmaceutical manufacturing, pharmaceutical commerce, pharmaceutical R&D, healthcare services, Chinese herbal medicine cultivation, modern agricultural product processing, and overall health and wellness.

Tags

Cardiovascular Diseases

Herbal medicine

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Top 5 Drug Type	Count

Herbal medicine	1
Small molecule drug	1

Drugs associated with Sichuan Gooddoctor Pharmaceutical Group Co. Ltd.

SanQi LongXueJie Capsule

Target-

Mechanism-

Active Org.

Yunnan Shengke Pharmaceutical Co., Ltd.

Originator Org.

Dihon Pharmaceutical Group Co., Ltd.

Active Indication

Cardiovascular Diseases

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date24 Oct 2019

GD-N1702

Target-

Mechanism-

Active Org.

Sichuan Gooddoctor Pharmaceutical Group Co. Ltd.

Originator Org.

Sichuan Gooddoctor Pharmaceutical Group Co. Ltd.

Active Indication

Heart Failure

Inactive Indication-

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with Sichuan Gooddoctor Pharmaceutical Group Co. Ltd.

CTR20221962 / CompletedPhase 1

评价GD-N1702胶囊在健康受试者中单次及多次给药的安全性、耐受性、药代动力学和药效动力学的随机、双盲、安慰剂对照的Ⅰ期临床研究

[Translation] A randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of GD-N1702 capsules in healthy subjects

主要目的：评价GD-N1702胶囊在中国健康成年受试者中单次和多次口服给药后的安全性和耐受性。次要目的：评估GD-N1702胶囊单次和多次口服给药后的药代动力学（PK）特征。

[Translation]

Primary objective: To evaluate the safety and tolerability of GD-N1702 capsules after single and multiple oral administration in healthy Chinese adult subjects. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of GD-N1702 capsules after single and multiple oral administration.

Start Date17 Oct 2022

Sponsor / Collaborator

Sichuan Gooddoctor Pharmaceutical Group Co. Ltd.

[+1]

CTR20221072 / CompletedNot Applicable

好医生药业集团有限公司研制的他达拉非片与原研参比制剂在中国健康男性受试者中进行的单中心、随机、开放、两制剂、空腹和餐后、单次给药、两周期、双交叉设计的生物等效性研究

[Translation] A single-center, randomized, open-label, two-dose, fasting and postprandial, single-dose, two-period, double-crossover bioequivalence study of tadalafil tablets developed by Good Doctor Pharmaceutical Group Co., Ltd. and the original reference preparation in healthy Chinese male subjects

以好医生药业集团有限公司研制的他达拉非片（规格：20 mg）为受试制剂，生产商为Lilly del Caribe, Inc. Puerto Rico（波多黎各）的他达拉非片（商品名：希爱力®/Cialis®，规格：20 mg）为参比制剂，考察两制剂在空腹及餐后状态下单次给药的药代动力学参数及相对生物利用度，评价两制剂是否具有生物等效性。同时评价两制剂在健康人体中的安全性和耐受性。

[Translation]

Tadalafil tablets (specification: 20 mg) developed by Good Doctor Pharmaceutical Group Co., Ltd. were used as the test preparation, and tadalafil tablets (trade name: Cialis®, specification: 20 mg) produced by Lilly del Caribe, Inc. Puerto Rico (Puerto Rico) were used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations after single administration in the fasting and postprandial states were investigated to evaluate whether the two preparations were bioequivalent. At the same time, the safety and tolerability of the two preparations in healthy humans were evaluated.

Start Date06 May 2022

Sponsor / Collaborator

Sichuan Gooddoctor Pharmaceutical Group Co. Ltd.

CTR20220278 / CompletedNot Applicable

青霉素V钾片在中国成年健康受试者中的一项随机、开放、空腹和餐后单次给药、两制剂、两序列、两周期交叉的生物等效性研究

[Translation] A randomized, open-label, single-dose, fasting and fed, two-formulation, two-sequence, two-period crossover bioequivalence study of penicillin V potassium tablets in healthy Chinese adult subjects

主要目的：观察单次口服0.25g（空腹/餐后）受试制剂青霉素V钾片（规格：0.25g/片，山西好医生药业有限公司生产）与参比制剂青霉素V钾片（规格：0.25g/片，Sandoz GmbH 生产）在中国成年健康受试者体内的吸收速度及吸收程度，初步评估空腹与餐后状态下分别口服两种制剂的人体生物等效性。次要目的：观察受试制剂和参比制剂单次口服0.25g（空腹/餐后）在中国成年健康受试者中的安全性。

[Translation]

Primary objective: To observe the absorption rate and extent of a single oral dose of 0.25g (fasting/after meals) of the test preparation Penicillin V Potassium Tablets (Specification: 0.25g/tablet, produced by Shanxi Good Doctor Pharmaceutical Co., Ltd.) and the reference preparation Penicillin V Potassium Tablets (Specification: 0.25g/tablet, produced by Sandoz GmbH) in healthy adult Chinese subjects, and to preliminarily evaluate the bioequivalence of the two preparations in humans when taken orally in fasting and after meals. Secondary objective: To observe the safety of a single oral dose of 0.25g (fasting/after meals) of the test preparation and the reference preparation in healthy adult Chinese subjects.

Start Date14 Feb 2022

Sponsor / Collaborator

Shanxi Good Doctor Pharmaceutical Co., Ltd.

100 Clinical Results associated with Sichuan Gooddoctor Pharmaceutical Group Co. Ltd.

0 Patents (Medical) associated with Sichuan Gooddoctor Pharmaceutical Group Co. Ltd.

Literatures (Medical) associated with Sichuan Gooddoctor Pharmaceutical Group Co. Ltd.

01 Jun 2024·Journal of Pharmaceutical and Biomedical Analysis

“Plant Golden” C. sativus: Qualitative and quantitative analysis of major components in stigmas and petals and their biological activity in vitro

Article

Author: Tan, Jin ; Song, Jiao ; Yang, Ming ; Geng, Funeng ; Pei, Jin ; Zhang, Dingkun ; Li, Xue ; Guan, Yongmei ; Ma, Hongyan

Crocus sativus L. (C. sativus) has its stigma as the main valuable part used. With extremely low production and high prices, stigma is considered a scarce resource. As a result, its petals, considered as by-products, are often discarded, leading to significant waste. We developed a UPLC-Q-Orbitrap HRMS method for qualitative analysis of stigmas and petals and a UHPLC-QQQ-MS/MS method for simultaneous quantification of 9 characteristic active compounds for the first time, and compared their biological activity in vitro. The results indicated that a total of 63 compounds were identified in the petals and stigmas. The content of flavonoids in the petals was significantly superior to that in the stigma, and the content of quercetin in the petals was 50 times higher than that in the stigma. The results of the in vitro evaluation of biological activity indicated that both the petals （•OH: IC₅₀=39.70 mg/mL; DPPH: IC₅₀=28.37 mg/mL; ABTS: IC₅₀=0.9868 mg/mL）and stigma （•OH: IC₅₀=34.41 mg/mL; DPPH: IC₅₀=38.99 mg/mL; ABTS: IC₅₀=3.194 mg/mL）demonstrated comparable antioxidant activities. However, the tyrosinase inhibitory activity in petals （IC₅₀=21.17 mg/mL） was weaker than that in stigma（IC₅₀=1.488 mg/mL）. This study provides a fast, reliable, and efficient analytical method that can be used for the quality assessment of petals as a natural resource and its related products in the food and pharmaceutical industries.

01 Jan 2024·Biomedicine & Pharmacotherapy

Ento-A alleviates DSS-induced experimental colitis in mice by remolding intestinal microbiota to regulate SCFAs metabolism and the Th17 signaling pathway

Article

Author: Zhao, Jie ; Wu, Taoqing ; Shen, Yongmei ; Wang, Dexiao ; Zhao, Yu ; Wang, Qian ; Zhang, Chenggui ; Gao, Pengfei ; Zhao, Hairong ; Liu, Heng ; Wu, Xiumei

Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by changes in the metabolism of short chain fatty acids (SCFAs), dysregulation of gut microbiota, and an imbalance of Treg/Th17. Herein, we explore the effects of the Ento-A (an alcohol extract of Periplaneta americana L.) on a mouse model of UC. First, a chronic and recurrent UC model was constructed in BALB/c mice by 2.2% DSS administration. UC mice were continuously treated for 14 days with Ento-A (50, 100, 200 mg/kg, i.g.) or a negative control. Ento-A alleviated many of the pathological changes observed in UC mice, such as body weight loss, disease activity index, changes in colon length, and colonic mucosal damage index. Ento-A also decreased levels of proinflammatory cytokines (IL-1β, IL-6, IL-17A, and TNF-α), increased levels of anti-inflammatory cytokines (IL-10 and TGF-β1) and repaired the intestinal mucosal barrier. Additionally, Ento-A regulated the proportions of Th17 cells, and Treg cells in mesenteric lymph nodes harvested from treated mice (as assessed by Flow cytometry), and the expression levels of IL-17A and Foxp3 in colon (as assessed by immunohistochemistry). 16 S rRNA gene sequencing revealed that Ento-A regulated gut microbiota. GC-MS analysis demonstrated that Ento-A also restored SCFAs content in the intestinal tract. Finally, transcriptomic analysis revealed that Ento-A regulated the IL-17 signaling pathway. In summary, Ento-A regulates the diversity and abundance of intestinal flora in UC mice, enhancing the secretion of SCFAs, subsequently regulating the IL-17 signaling pathway, and ultimately repairing the intestinal mucosal barrier.

01 Sep 2023·Phytomedicine

Guizhi Shaoyao Zhimu granules attenuate bone destruction in mice with collagen-induced arthritis by promoting mitophagy of osteoclast precursors to inhibit osteoclastogenesis

Article

Author: Yao, Huan ; Li, Xueping ; Shen, Yongmei ; Xiang, Li ; Geng, Funeng ; Li, Fangqiong ; Liu, Weiwei ; Tan, Jin ; Huang, Yucheng ; Gao, Yongxiang

BACKGROUNDGuizhi Shaoyao Zhimu decoction, a traditional Chinese medicine formula used empirically for the treatment of rheumatoid arthritis (RA), has been shown to alleviate bone destruction in rats with collagen-induced arthritis (CIA).PURPOSEThe aim of this study is to characterize the effects of Guizhi Shaoyao Zhimu granules (GSZGs) on bone destruction in RA and the underlying mechanism.STUDY DESIGNA CIA arthritis model using DBA/1 mice. The animals were divided into a normal group; CIA model group; low, medium, and high-dose GSZG groups (3, 6, and 9 g/kg/day); and a methotrexate group (1.14 mg/kg/w). In vitro, a cytokine induced osteoclastogenesis model was established.METHODSAfter 28 days of treatment, the paw volume was measured, bone destruction was examined by micro-CT, and the generation of osteoclasts in bone tissue was evaluated via tartrate-resistant acid phosphatase (TRAP) staining. Furthermore, the inhibitory effect and underlying mechanism of action of GSZG on RANKL-induced osteoclastogenesis were investigated in vitro.RESULTSThe in vivo analyses demonstrated that the paw volume and degree of bone erosion of mice in the medium- and high-dose GSZG groups were significantly decreased compared to the CIA model group. In addition, GSZG treatment suppressed the excessive generation of osteoclasts in the bone tissue of CIA mice. In vitro, GSZG inhibited RANKL-induced osteoclastogenesis and osteoclast-mediated bone resorption. Specifically, it only inhibited the generation of osteoclast precursors (OCPs); it had no significant effect on the fusion of OCPs or maturation of osteoclasts. Finally, we showed that the inhibitory effect of GSZG on osteoclastogenesis was related to the promotion of PTEN-induced kinase protein 1 (PINK1)/Parkin pathway-mediated mitophagy of osteoclast precursors, which was verified using a PINK1 knockdown small interfering RNA in OCPs.CONCLUSIONThese findings indicate that GSZG is a candidate for the treatment of bone destruction in RA and provide a more detailed elucidation of the mechanism of GSZG anti-RA bone erosion, i.e., inhibition of the ROS/NF-κB axis through the PINK1/Parkin-mediated mitochondrial autophagic pathway to inhibit osteoclast precursor production, compared to the published literature.

100 Deals associated with Sichuan Gooddoctor Pharmaceutical Group Co. Ltd.

100 Translational Medicine associated with Sichuan Gooddoctor Pharmaceutical Group Co. Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 08 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

Approved

Current Projects

Drug(Targets)	Indications	Global Highest Phase

SanQi LongXueJie Capsule	Cardiovascular Diseases More	Approved
GD-N1702	-	Phase 1

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis